Showing results (21-30 of 439) with videos related to
Sort By:
Pageof 44
Expert Review of Hematology|December 22, 2018
Intravenous arsenic trioxide and all-trans retinoic acid as front-line therapy for low-risk acute promyelocytic leukemiaMassimo Breccia, Robin FoàExpert Opinion on Drug Safety|August 21, 2010
Pleural/pericardic effusions during dasatinib treatment: incidence, management and risk factors associated to their developmentMassimo Breccia, Giuliana AlimenaExpert Opinion on Pharmacotherapy|July 5, 2011
The current role of high-dose imatinib in chronic myeloid leukemia patients, newly diagnosed or resistant to standard doseMassimo Breccia, Giuliana AlimenaCancers|November 13, 2025
Challenges in the Evolving Role of Calreticulin as a Promising Target for Precision Medicine in Myeloproliferative NeoplasmsAlessandro Costa, Massimo BrecciaBritish Journal of Haematology|December 27, 2023
How to improve treatment-free remission eligibility in chronic myeloid leukaemia?Alessandro Costa, Massimo BrecciaOncotargets and Therapy|December 4, 2010
Refining targeted therapies in chronic myeloid leukemia: development and application of nilotinib, a step beyond imatinibMassimo Breccia, Giuliana AlimenaCritical Reviews in Oncology/Hematology|August 6, 2010
The significance of early, major and stable molecular responses in chronic myeloid leukemia in the imatinib eraMassimo Breccia, Giuliana AlimenaCancer Letters|February 11, 2014
Discontinuation of tyrosine kinase inhibitors and new approaches to target leukemic stem cells: treatment-free remission as a new goal in chronic myeloid leukemiaMassimo Breccia, Giuliana AlimenaClinical Lymphoma, Myeloma & Leukemia|February 7, 2025
SOHO State of the Art Updates and Next Questions: Combination Therapy in Chronic Myeloid Leukemia in Chronic PhaseAlessandro Costa, Massimo BrecciaDrugs & Aging|April 26, 2013
Management options for refractory chronic myeloid leukemia: considerations for the elderlyMassimo Breccia, Giuliana AlimenaPageof 44